CT023 - Phase 1 trial of CD19/CD20 bispecific chimeric antigen receptor-engineered naïve/memory T cells for relapsed or refractory non-Hodgkin lymphoma
Last Updated: Friday, May 19, 2023
An investigational CD19/20-directed CAR T-cell therapy had a 91% overall response rate among adults with advanced non-Hodgkin lymphoma. The median overall survival has not yet been reached, with some remissions lasting more than 3 years post-infusion.
Advertisement
News & Literature Highlights